雷珠单抗联合激光治疗视网膜静脉阻塞继发黄斑水肿患者的效果  

Effects of Ranibizumab combined with laser in treatment of macular edema secondary to retinal vein occlusion

作　　者：张兰兰 ZHANG Lanlan(Department of Pharmacy of Anyang Eye Hospital,Anyang 455000 Henan,China)

机构地区：[1]安阳市眼科医院药剂科,河南安阳455000

出　　处：《中国民康医学》2024年第10期53-56,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察雷珠单抗联合激光治疗视网膜静脉阻塞(RVO)继发黄斑水肿患者的效果。方法:回顾性分析2021年7月至2023年3月该院收治的78例RVO继发黄斑水肿患者的临床资料,根据治疗方案不同将其分为对照组与研究组各39例。对照组采用视网膜激光光凝术治疗,研究组在激光手术前联合玻璃体腔注射雷珠单抗治疗。比较两组临床疗效,治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、房水炎性因子[白细胞介素-8(IL-8)、单核细胞趋化蛋白-1(MCP-1)、基质细胞衍生因子-1(SDF-1)]水平、血管内皮生长因子(VEGF)水平,以及并发症发生率。结果:研究组总有效率为92.31%(36/39),高于对照组的74.36%(29/39),差异有统计学意义(P<0.05);治疗3个月后,研究组BCVA、CMT值均小于对照组,房水IL-8、MCP-1、SDF-1、VEGF水平均低于对照组,差异有统计学意义(P<0.05);研究组并发症发生率为5.13%(2/39),低于对照组的23.08%(9/39),差异有统计学意义(P<0.05)。结论:雷珠单抗联合激光治疗RVO继发黄斑水肿患者效果显著,可减小CMT值,促进视力恢复,降低房水炎性因子、VEGF水平及并发症发生率,效果优于单用激光治疗。Objective:To observe effects of Ranibizumab combined with laser in treatment of macular edema secondary to retinal vein occlusion(RVO).Methods:The clinical data of 78 patients with macular edema secondary to RVO admitted to this hospital from July 2021 to March 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and study group,39 cases in each group.The control group was treated with retinal laser photocoagulation,while the study group was treated with intravitreal injection of Ranibizumab before the laser surgery.The clinical efficacy,the best corrected visual acuity(BCVA),the central macular thickness(CMT),the aqueous humor inflammatory factors[interleukin-8(IL-8),monocyte chemoattractant protein-1(MCP-1),stromal cell derived factor-1(SDF-1)]levels,the vascular endothelial growth factor(VEGF)levels,and the incidence of complications were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 92.31%(36/39),which was higher than 74.36%(29/39)of the control group,and the difference was statistically significant(P<0.05).After 3 months of treatment,the BCVA and CMT values of the study group were lower than those of the control group,the levels of IL-8,MCP-1,SDF-1 and VEGF in aqueous humor were lower than those of the control group,and the differences were statistically significant(P<0.05).Further,the incidence of complications in the study group was 5.13%(2/39),which was lower than 23.08%(9/39)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Ranibizumab combined with laser is effective in the treatment of macular edema secondary to RVO.It can reduce the macular edema,promote the visual recovery,and reduce the levels of inflammatory factors and VEGF in aqueous humor and the incidence of complications.Moreover,it is superior to single laser treatment.

关 键 词：雷珠单抗 激光 视网膜静脉阻塞 黄斑水肿 玻璃体腔注射 血管内皮生长因子 

分 类 号：R774.5[医药卫生—眼科]